SCHEMBL2138368

SCHEMBL2138368

Cc1ccc(S(=O)(=O)[O-])cc1.[Cu+]

nearest known ligand 0.62

Known targets — ChEMBL curated mechanism

CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.62
CA1 P00915 4/20 0.56
CA2 P00918 4/20 0.56
CA12 O43570 2/20 0.56
CA9 Q16790 2/20 0.56
CA3 P07451 1/20 0.56
CA6 P23280 1/20 0.56
CA5A P35218 1/20 0.56
CA7 P43166 1/20 0.56
CA5B Q9Y2D0 1/20 0.56
TLR9 Q9NR96 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.52
ALDH1A1 P00352 4/20 0.50
TDP1 Q9NUW8 3/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28465424 0.97 GAA (0.59) GAACA1CA2CA12CA9
SCHEMBL8943267 0.94 GAA (0.62) GAACA1CA2CA12CA9
SCHEMBL6917586 0.94 GAA (0.62) GAACA1CA2CA12CA9
SCHEMBL8954960 0.94 GAA (0.62) GAACA1CA2CA12CA9
SCHEMBL11815250 0.94 GAA (0.62) GAACA1CA2CA12CA9
SCHEMBL10663598 0.94 GAA (0.62) GAACA1CA2CA12CA9
SCHEMBL8617002 0.94 GAA (0.62) GAACA1CA2CA12CA9
SCHEMBL22615914 0.94 GAA (0.62) GAACA1CA2CA12CA9
SCHEMBL20583857 0.94 GAA (0.62) GAACA1CA2CA12CA9
SCHEMBL3180420 0.94 GAA (0.62) GAACA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116554245-A Glycosylation method with participation of trivalent iodine reagent 华中科技大学 2023-08-08 CN disclosed
CN-106978617-B Method for electroplating metal in recessed structure 台湾积体电路制造股份有限公司 2022-01-04 CN disclosed
CN-108031489-B Preparation method and application of fly ash-supported copper p-toluenesulfonate catalyst 南京科技职业学院 2020-11-17 CN disclosed
CN-108031489-A A kind of preparation method and applications of the immobilized copper p-toluene sulfonate catalysis of flyash 南京科技职业学院 2018-05-15 CN disclosed
EP-1911516-B1 HOMOGENEOUS ASYMMETRIC HYDROGENATION PROCESS TAKASAGO PERFUMERY CO LTD (JP) 2014-05-14 EP disclosed
EP-2392400-B1 Homogeneous asymmetric hydrogenation method TAKASAGO PERFUMERY CO LTD (JP) 2014-05-07 EP disclosed
US-8586498-B2 Homogeneous asymmetric hydrogenation catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-11-19 US disclosed
CN-102675096-B Method for preparing butyl stearate TAICANG HUSHI REAGENT CO LTD 2013-11-06 CN disclosed
US-8497400-B2 Homogeneous asymmetric hydrogenation process TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-07-30 US disclosed
US-8481791-B2 Homogeneous asymmetric hydrogenation process TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-07-09 US disclosed
EP-2095875-A1 Homogeneous asymmetric hydrogenation catalyst Takasago International Corporation (JP) 2009-09-02 EP disclosed
US-20090203927-A1 Homogeneous asymmetric hydrogenation catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-08-13 US disclosed
EP-1911516-A1 HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST Takasago International Corporation (JP) 2008-04-16 EP disclosed
EP-1395547-B1 COPPER-CATALYZED VAPOR PHASE HYDROCYANATION OF DIOLEFINIC COMPOUNDS INVISTA TECH SARL (US) 2005-03-16 EP disclosed
US-6753440-B2 CATALYZING THE REACTION IN PRESENCE OF A CATALYST SUPPORTS CONTAINING COPPER (I) OR (II) FLUORINATED ALKYLSULFONATE COMPLEXES E.I. DU PONT DE NEMOURS AND COMPANY 2004-06-22 US disclosed
US-20030045740-A1 Copper-catalyzed vapor phase hydrocyanation of diolefinic compounds INVISTA NORTH AMERICA S.A.R.L. 2003-03-06 US disclosed
EP-0395144-B1 A PROCESS FOR THE PREPARATION OF AROMATIC UREAS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1993-06-30 EP disclosed
EP-0395144-A1 A process for the preparation of aromatic ureas SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1990-10-31 EP disclosed
EP-0393789-A1 A process for the preparation of carbamates SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1990-10-24 EP disclosed
US-4721819-A Process for the preparation of higher allylic ethers SHELL OIL COMPANY (US) 1988-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045740-A1 Copper-catalyzed vapor phase hydrocyanation of diolefinic compounds AOC1, AOC2, C9 GAA 3743/4885CA1 285/4885CA2 965/4885
US-20090203927-A1 Homogeneous asymmetric hydrogenation catalyst HDHD5, HHAT, HACL2 GAA 2576/4885CA1 1609/4885CA2 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.